Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ohr Pharmaceutical, Inc.
New York, New York, United Statesohrpharmaceutical.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Squalamine in combination with Lucentis for wet AMD did not meet primary efficacy endpoint in January 2018. The company merged with NeuBase Therapeutics in 2019, with NeuBase stockholders becoming majority holders.
- Therapeutic areas
- OphthalmologyOncologyImmunologyNeurology
- Modalities
- Small moleculespeptide-nucleic acid (PNA) antisense oligonucleotide
- Industry
- Biotech
02
Partnerships
Cold Spring Harbor Laboratory
Beyond the preview
Go deeper on Ohr Pharmaceutical, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ohr Pharmaceutical, Inc..